FR117016

FR117016 is an experimental small molecule drug belonging to the benzimidazole class. It acts as a highly potent non-nucleoside inhibitor of adenosine deaminase (ADA), with a reported inhibition constant (Ki) of 7.7 nM. The compound was discovered through structure-based drug design and intentional lead hybridization strategies. Its mechanism involves binding to ADA and stabilizing it in an open conformation that inhibits its enzymatic activity. The primary developer is Fujisawa Pharmaceutical Co., Ltd., Japan[8][10][5]. There are no approved indications or clinical trials beyond preclinical research.

Other names

2-(4-{5-[(1H-1,3-benzodiazol-2-ylamino)methyl]thiophen-2-yl}-1,3-thiazol-2-yl)guanidineN''-(4-(5-((1H-BENZIMIDAZOL-2-YLAMINO)METHYL)-2-THIENYL)-1,3-thiazol-2-YL)GUANIDINE1ndv